Pulmonary Embolism Management Guidelines

Risk Stratification and Acute Phase Management

The European Society of Cardiology recommends that all patients with suspected or confirmed pulmonary embolism (PE) must be stratified based on hemodynamic stability to identify those at high risk of early mortality 1
High-risk PE is defined by hemodynamic instability with systolic blood pressure <90 mm Hg or cardiogenic shock, and requires immediate bedside echocardiography or emergency CTPA depending on availability 1, 2
The American Thoracic Society recommends that patients with intermediate-risk PE, characterized by right ventricular dysfunction and/or myocardial injury but without hemodynamic instability, should be further stratified into intermediate-high and intermediate-low risk categories to guide management 1
Low-risk PE patients, who are hemodynamically stable without evidence of right ventricular dysfunction or myocardial injury, are candidates for early discharge and home treatment 3

The European Heart Journal recommends initiating intravenous unfractionated heparin with a weight-adjusted bolus immediately without waiting for diagnostic confirmation in suspected high-risk PE 1, 3
Systemic thrombolytic therapy is the definitive treatment for high-risk PE presenting with cardiogenic shock and/or persistent arterial hypotension (Class I recommendation) 4, 1, 2
Vasopressor support with norepinephrine and/or dobutamine should be considered for hemodynamic support in high-risk PE patients 4, 3
Aggressive fluid challenge is not recommended as it may worsen right ventricular failure 4

The European Society of Cardiology recommends that when initiating oral anticoagulation in PE patients eligible for a direct oral anticoagulant (DOAC), a DOAC should be preferred over vitamin K antagonists 1, 3
DOACs such as apixaban, dabigatran, edoxaban, or rivaroxaban are options for oral anticoagulation, with specific dosing recommendations 1, 3
Vitamin K antagonists may be used as an alternative, with overlap with parenteral anticoagulation until INR reaches 2.5 (range 2.0-3.0) for at least 2 consecutive days 4, 3

The European Heart Journal recommends that routine use of inferior vena cava (IVC) filters is not recommended, but may be considered in patients with acute PE and absolute contraindications to anticoagulation 1, 3
In patients with severe renal impairment, unfractionated heparin should be used instead of low molecular weight heparin (LMWH) or fondaparinux, and DOACs are contraindicated 4, 1
During pregnancy or postpartum, formal diagnostic assessment with validated methods should be performed if PE is suspected, and DOACs are contraindicated 1, 3